OBJECTIVES: Resection of N2a non-small-cell lung cancer (NSCLC) diagnosed preoperatively is controversial but there is support for resection of unexpected N2 disease discovered at surgery. Since the seventh TNM edition, we have intentionally resected clinical N2a disease. To validate this policy, we determined prognostic factors associated with all resected N2 disease.
INTRODUCTION
The role of surgery for Stage IIIA-N2 non-small-cell lung cancer (NSCLC) remains undetermined. In the seventh edition of the TNM staging system, the relatively favourable prognosis of single pathological zone N2 disease (N2a) was identified but could not be formally validated. Nevertheless, resection of N2a NSCLC diagnosed preoperatively is not universally accepted, whilst paradoxically there is support for resection of unexpected N2 disease discovered intraoperatively rather than closing without resection [1] . Since the publication of the seventh TNM edition in May 2009 [2] , we have intentionally resected clinical N2a disease with a prospective analysis of outcomes. The aim of this study was to validate our policy by comparing the postoperative outcomes of patients with clinical N2a with those clinically staged cN0 or cN1 on preoperative positron emission computed tomography (PET-CT), but who were found to have pN2 disease.
MATERIALS AND METHODS
From a prospective histological database of 1131 consecutive cases of NSCLC resected over 8 years (May 2004-January 2012), we identified 68 patients [33 males; 35 females, mean age 65.9 (standard deviation, SD 9.3) years] who underwent resection for pathological N2 disease. All patients had clinical nodal staging with PET-CT and a selective mediastinoscopy was performed on patients with either PET positive mediastinal lymph nodes or when the multidisciplinary team required exclusion of multizone N2 disease. Intraoperative staging comprised a lobe-specific systematic mediastinal lymph node dissection [3] .
Ten patients had received neoadjuvant chemotherapy (CT) prior to surgical resection and adjuvant treatment was given as follows: 14 patients (20.5%) received and completed adjuvant chemotherapy only with cisplatin-based regimens, 4 patients (5.8%) received postoperative radiotherapy (RT) only and 9 patients (13.2%) received combined RT and chemotherapy postoperatively. No adjuvant chemoradiotherapy was given to 41 patients.
Data were collected from the hospital's electronic patient records, case notes and our Trust's web-deployable imaging management software.
Patients were analysed in two groups: patients with PET-CT positive N2 nodes preoperatively (group PETP) and patients with CT-PET negative N2 nodes (group PETN). The groups were compared with respect to age, gender, T stage, preoperative forced expiratory volume (FEV1), histology, rate of R0 resection, recurrence rate, receipt of chemotherapy and survival.
All patients were followed up in regular intervals postoperatively (3, 6, 9, 12, 24, 36, 48 , 60 m) with regular clinic appointments, chest radiographs and/or CT scan if there was a clinical or radiological suspicion of recurrence. Patients receiving adjuvant therapy were also followed up with a CT scan organized between surgical and oncology teams after completion of their chemo-or RT sessions. Additional information was obtained, where required, from Oncology departments.
Statistical analysis
We used the IBM SPSS Statistics for Windows, Version 19.0. Armonk, NY: IBM Corp. for analysis: continuous data were analysed using Student's unpaired t-test and categorical data with Fisher's exact test. Survival curves were estimated using the Kaplan-Meier method. Follow-up was quantified with the reverse Kaplan-Meier estimator. Univariate analysis of survival was performed using the log-rank test. The prognostic factors shown statistically significant on univariate analysis were included in a multivariate analysis, using Cox-regression models. A probability value <0.05 was considered statistically significant.
RESULTS
A preoperative mediastinoscopy was only performed in 14 out of 30 patients who were staged cN2 on preoperative PET-CT scan. Two of them were positive confirming the presence of NSCLC in lymph nodes with avid standardized uptake value on preoperative scan (station 4L for a left upper lobe tumour and 7 for a right lower lobe tumour, respectively). No mediastinoscopies were performed on patients with cN0-N1 on PET.
There were no significant intergroup differences in any of the clinical or pathological characteristics of the 68 patients [ Tables 1  and 2 ]. There were four in-hospital deaths (5.8%). The mean hospital stay for all patients was 10.3 days (SD 12.5 days). The overall median follow-up was 38.7 months [standard error 10, 95% confidence interval (CI) 19.0-58.4].
The anatomical resections performed included: lobectomy in 29 patients, bilobectomy in 5, sleeve lobectomy in 10, segmentectomy in 9 and pneumonectomy in 15. Of the 68 patients who underwent resection for pN2 NSCLC in this study, 30 patients were clinically staged as N2 on preoperative PET-CT (group PETP), whilst 38 patients were clinically staged as N0 or N1 (group PETN). In group PETP, 28 patients had single-zone disease on PET-CT staging (cN2a), whilst 2 had multizone cN2b disease (1 patient with positive stations 4L and 5 and the other one positive in stations 7 and 8). In group PETN, 16 patients had cN1, whilst 22 were cN0.
Analysis of the resected pathological data showed that 55 of the 68 cases were proven to have pN2a (single zone) disease: 30 subcarinal, 17 aortopulmonary, 6 upper mediastinal and 2 lower mediastinal. In the remaining 13 cases of pN2b (multizone) disease, only one had preoperative cN2b disease but had a negative mediastinoscopy. Three further patients in this group had cN2a disease but the majority had cN0/1 disease: 7 were cN0 and 2 cN1.
Survival
There was no significant difference in progression-free survival (PFS) between group PETP (median PFS 14.4 months, 95% CI 6.4-22.4) and group PETN (median PFS 17.6 months, 95% CI 1.5-33.5, P = 0.16) [ Fig. 1] .
Analysis of overall survival (OS) has also shown no intergroup difference: PETP (median survival 22.2 months, 95% CI 10.9-37.1) and PETN (median survival 24 months, 95% CI 10.9-33.9, P = 0.33) [ Fig. 2 ].
In the subgroup of patients that had proven single-zone pN2a, the survival was significantly better than for the patients with resected multizone pN2b disease (median OS 26.5 months vs 5.4 months, P = 0.005) [ Fig. 3 ]. The results of univariate analysis of clinical and pathological related features [ Table 3 ] showed the following variables to be associated with a poorer prognosis: multizone pN2b (P = 0.007), pneumonectomy (P = 0.005) and no adjuvant chemotherapy (P = 0.012). No difference in survival was associated with: gender, CT-PET positive cN2, lower mediastinal zone pN2, upper mediastinal zone pN2 or aortopulmonary zone pN2. There was a non-significant trend between adverse prognosis and pathological involvement of subcarinal zone pN2 (P = 0.063).
Multivariate analysis using Cox regression showed multizone pN2b involvement (hazard ratio (HR) 2.34, 95% CI 1.01-5.40, P = 0.047) and receipt of adjuvant chemotherapy (HR 0.42, 95% CI 0.21-0.85, P = 0.016) to be significant prognostic factors [ Table 4 ].
DISCUSSION

Summary of results
Our study showed a low incidence of resected pN2 (68 out of 1131 patients, 6%) that can be attributed to the efficacy and wide use of PET-CT in the preoperative assessment of patients. Only 2 patients were identified as cN2b preoperatively and 1 of them had a negative mediastinoscopy subsequently. The analysis of the International Association for the Study of Lung Cancer database showed that median survival for the two subgroups of surgically treated pN2 disease was 35 months for pN2a compared with 19 months for pN2b disease [4] . Our results show a lower survival (26.5 months for pN2a vs 5.4 months for pN2b) especially for the multizone N2 group that can be attributed to the small non-randomized nature of the study as well as poor compliance with adjuvant chemotherapy.
The heterogeneity of the subgroup of patients with Stage IIIA-N2 NSCLC with regard to prognosis and treatment has not allowed for a consensus on the management of the disease. Numerous investigators have focused on recognizing clinical and pathological prognostic factors [5] [6] [7] . Large multiinstitutional studies [8] have also described correlation between clinical N status, number of N2 stations involved and survival. In the latest revision of TNM staging, there were three distinct prognostic groups among patients undergoing resection without induction therapy: single pathological N1 zone, multiple pathological N1 zones or single pathological N2 zone, and multiple pathological N2 zone disease. However, analysis of the above N categories in conjunction with each T category (e.g. T1N1a, T1N1b, T1N2a, T1N2b, etc.) identified insufficiently large numbers to yield statistically valid analysis. Therefore, the change of N descriptors was not recommended [4] . Nevertheless, the preoperative finding of N2 in multiple levels is related with poor prognosis, similar to Stage IIIB, but the presence of incidental N2a (cN0-N1) depicts a subgroup with good prognosis.
Preoperative mediastinoscopy
Detailed mediastinal nodal staging has resulted in several studies confirming the superiority of PET-CT over CT [9] [10] [11] . Whilst cervical mediastinoscopy is superior to both CT and PET-CT, it should not be employed in all cases. Its nonselective use amongst Stage 1 NSCLC has not been proven to be cost-effective [12] . Other invasive techniques for sampling of mediastinal stations not accessible by cervical mediastinoscopy, such as videothoracoscopy, have also been suggested [13] . One of our main conclusions is that preoperative mediastinoscopy should be used to confirm N2a disease by showing that the other mediastinal lymph node zones are negative. Recently Yasufuku et al. [14] found that endobronchial ultrasound-guided trans-bronchial needle aspiration (EBUS-TBNA) and oesophageal ultrasoundguided fine needle aspiration (EUS-FNA) were highly effective in the radiologically normal mediastinum with a sensitivity of up to 68% and a negative predictive value (NPV) of 91%. However, we prefer mediastinoscopy to the less invasive techniques of EBUS-TBNA or EUS-FNA since in the potential surgical patients with suspected N2 disease on a PET-CT scan the conclusions are different as shown in two recent papers, where EBUS-TBNA and EUS-FNA had an NPV of 79% and sensitivity of only 57% but mediastinoscopy had better results with 88% sensitivity, 93% NPV and 95% accuracy [15, 16] .
The majority of our pN2 patients had pathologically proven involvement of the subcarinal zone (41/68, 60.3%). Eleven out of these patients had mediastinoscopy with only 1 showing positive subcarinal lymph nodes. This finding highlights the technical challenges of this procedure as well as the importance 
Intraoperative staging
In view of the above results, we recommend systematic mediastinal lymph node dissection, especially when N2 disease has been identified preoperatively, to achieve an accurate nodal staging and guide the therapeutic strategy. However, we recognize that this approach does not hold a survival advantage over systematic sampling [17, 18] . Detterbeck [1] has shown in his study no demonstrably different quality of life nor significantly increased perioperative mortality between exploratory thoracotomy and lobectomy when assessing the appropriateness for resection of what he describes as 'surprise N2 disease'. Our results though support his conclusion that one should proceed with resection only in pN2a but not pN2b disease.
We acknowledge that alternative strategies need to be considered especially for patients who would not tolerate a surgical approach. Randomized studies have recently shown no benefit in survival between induction chemoradiation vs induction chemotherapy alone prior to subsequent surgical resection [19] . Albain et al. [20] have also shown in their Phase III study significantly improved PFS but not OS when comparing concurrent CT and RT (C/R) vs C/R followed by surgical resection on selected patients with histologically or cytologically proven Stage IIIA-N2 NSCLC. None of these studies, however, quoted specific survival data for pN2a and pN2b disease, making direct comparison difficult.
Limitations
The small number of this series, 68 patients with pathological N2 disease, is a definite limitation of the study. Also, its retrospective nature meant that, during the 8 years (2004-2012) reviewed, three different TNM classifications as well as different imaging modalities (CT, PET-CT) were used, the technical aspects of which have changed. The clinical staging followed in our study, consisting of lobe-specific systematic mediastinal lymph node dissection, resulted in failure to identify clinical N2b disease in 13 patients, who subsequently underwent lung resection with very poor survival (overall median survival was 5.4 months). In retrospect, our pN2 might have been higher if a systematic nodal dissection was applied. We would also like to highlight the fact that 13 of the patients underwent pneumonectomy, which is known to be associated with a high rate of delayed cardio-respiratory complications. Therefore, our mortality rates could have been lower if a different end point had been applied other than death from any cause.
Conclusion
Our results have shown no significant difference in survival between those patients with negative preoperative PET-CT who are found to have pN2 disease after resection and those who are single-zone cN2 positive before resection. Therefore, the answer to the paradox is that if the surgeon would proceed to resection for intraoperatively detected N2 disease, then he is justified to proceed to resection for preoperatively identified single-zone N2a disease. However, confirmatory mediastinoscopy should be routinely performed in this treatment schedule. Also surgery should be part of a multimodality treatment with adjuvant chemotherapy as has been demonstrated in our study.
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